Protalix BioTherapeutics (PLX)

Executive Summary

Protalix BioTherapeutics is a biopharmaceutical company specializing in recombinant therapeutic proteins produced via its proprietary ProCellEx® plant cell-based expression system. The company's primary approved product, Elelyso® (taliglucerase alfa), is an enzyme replacement therapy for Gaucher disease, marketed in partnership with Pfizer. Protalix is advancing a pipeline of investigational therapies for rare diseases, most notably PRX-102 for Fabry disease, which has completed Phase III trials and is under regulatory review. With a fully integrated manufacturing facility in Israel, Protalix maintains control over its production process. The company faces both opportunities and risks: Elelyso provides recurring revenue, but competition from other ERTs may limit growth. The Fabry disease program represents a significant value driver if approved, though regulatory outcomes remain uncertain. Protalix's plant-based technology offers potential cost advantages and scalability. The company's financial position, including its market cap of approximately $172 million, reflects the market's cautious optimism pending key regulatory milestones. Successful commercialization of PRX-102 and expansion of Elelyso's market share are critical for long-term value creation.

Upcoming Catalysts (preview)

• Q1 2026FDA decision on PRX-102 for Fabry disease65% success
• Q2 2026Commercial partnership for PRX-102 outside US50% success
• Q3 2026Elelyso sales update and potential new market approvals70% success